Genexine Announces Dosing of First Patient in Phase 2 clinical trial with Triple Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)

Press/Media: Press / Media

Period2022 Aug 17

Media coverage

10

Media coverage